

STN

=> d his

(FILE MEDLINE ENTERED AT 14:19:31 ON 25 SEP 2007)

FILE MEDLINE ENTERED AT 14:19:31 ON 25 SEP 2007

R AND 2173

F AZD2171/CN

F AZD 2171/CN

L1 1 S E3

0 FILE MEDLINE

L2 1 S E3

FILE MEDLINE BIOSIS EMBASE CAPLUS USPATFULL USPATOLD USPA12

ENTERED AT 14:19:31 ON 25 SEP 2007

SET MEDLINE

L3 0 FILE MEDLINE

L4 0 FILE BIOSIS

L5 0 FILE EMBASE

L6 40 FILE CAPLUS

L7 12 FILE USPATFULL

L8 0 FILE USPATOLD

L9 0 FILE USPAT2

TOTAL FOR ALL FILES

L10 53 S L1

L11 0 FILE MEDLINE

L12 73 FILE BIOSIS

L13 173 FILE EMBASE

L14 73 FILE CAPLUS

L15 12 FILE USPATFULL

L16 0 FILE USPATOLD

L17 1 FILE USPAT2

TOTAL FOR ALL FILES

L18 332 S L2

L19 0 FILE MEDLINE

L20 0 FILE BIOSIS

L21 0 FILE EMBASE

L22 3 FILE CAPLUS

L23 2 FILE USPATFULL

L24 0 FILE USPATOLD

L25 0 FILE USPAT2

TOTAL FOR ALL FILES

L26 5 S L18 AND L10

=> d 126 1-6 lib kwic

L26 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:536292 CAPLUS

DOCUMENT NUMBER: 147:8399

TITLE: Anti-neuropilin 1 antagonistic antibodies for research, diagnosis and therapy of cancer and angiogenesis-associated disease

INVENTOR(S): Watts, Ryan J., Wu, Yan

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 83pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007056470	A2	20070518	WO 2006-US43516	20061108
WO 2007056470	A3	20070809		

W. AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MK, MN, MW, MX, MY, MZ, NA, NC, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TF, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-734798P P 20051108
US 2006-820561P P 20060727

IT 111358-88-4, CEP-701 120685-11-2, PKC-412 139987-54-5, OSI-7904
152459-95-5, Imatinib 179324-69-7, VELCADE 183321-74-6, Erlotinib
184475-35-2, ZD1839 194413-58-6, Semaxanib 212141-54-3, Vatalanib
216974-75-3, Bevacizumab 219923-05-4, ZD6126 231277-92-2,
Lapatinib 284461-73-0, Sorafenib 288383-20-0, AZD2171
347396-82-1, Ranibizumab 387867-13-2, MLN-518 443913-73-3, ZD6474
453562-69-1, AMG706 557795-19-4, Sunitinib 777080-36-1, AG 13736
937176-80-2, EXEL 2880 937178-31-9, CHIR 265

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anti-neuropilin 1 antagonistic antibodies for research, diagnosis and therapy of cancer and angiogenesis-associated disease)

L26 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:332801 CAPLUS

DOCUMENT NUMBER: 146:309324

TITLE: Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)

INVENTOR(S): Verschraegen, Claire

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 16pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007065449	A1	20070322	US 2006-522687	20060915

PRIORITY APPLN. INFO.: US 2005-717652P P 20050916

IT 95058-81-4, Gemcitabine 114977-28-5, Docetaxel 204005-46-9, SU5416
212142-18-2, PTK787 216974-75-3, Bevacizumab 219923-05-4,
ZD6126 252916-29-3, SU6668 257938-36-6, ZD4190 288383-20-0,
AZD2171 341031-54-7, SU11248 402857-58-3, CEP-7055 443913-73-3,
ZD6474

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treating soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab))

L26 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:55068 CAPLUS
DOCUMENT NUMBER: 142:127565
TITLE: AZD2171-ZD6126 combination with optional ionizing radiation for the production of an antiangiogenic and/or vascular permeability-reducing effect and the treatment of cancer
INVENTOR(S): Wedge, Stephen Robert
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005004871	A1	20050120	WO 2004-GB2937	20040707
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004255023	A1	20050120	AU 2004-255023	20040707
CA 2531643	A1	20050120	CA 2004-2531643	20040707
EP 1651227	A1	20060503	EP 2004-743280	20040707
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1819830	A	20060816	CN 2004-80019488	20040707
BR 2004012450	A	20060919	BR 2004-12450	20040707
JP 2007526887	T	20070920	JP 2006-518354	20040707
NO 2005006171	A	20060207	NO 2005-6171	20051223
US 2006160775	A1	20060720	US 2006-563440	20060105
MX 2006PA00413	A	20060317	MX 2006-PA413	20060110
PRIORITY APPLN. INFO.:			GB 2003-16123	A 20030710
			WO 2004-GB2937	W 20040707

REFERENCE COUNT: 1. THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 219923-05-4, ZD6126 288383-20-0, AZD 2171 824933-09-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(AZD2171-ZD6126 combination with optional ionizing radiation for production of antiangiogenic and/or vascular permeability-reducing effect and treatment of cancer)

L26 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2007:75099 USPATFULL
TITLE: Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
INVENTOR(S): Verschraegen, Claire Albuquerque, NM, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2007065449 A1 20070322
APPLICATION INFO.: US 2006-522687 A1 20060915 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-717652P	20050915 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	COLEMAN SUDOL SAPONE, P.C., 711 COLORADO AVENUE, BRIDGE PORT, CT, 06605-1601, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1545	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 95058-81-4, Gemcitabine 114977-28-5, Docetaxel 204005-46-9, SU5416
212142-18-2, PTK787 216974-75-3, Bevacizumab 219923-05-4,
ZD6126 252916-29-3, SU6668 257938-36-6, ZD4190 288383-20-0,
AZD2171 341031-54-7, SU11248 402857-58-3, CEP-7055 443913-73-3,
ZD6474

(treating soft tissue sarcoma utilizing gemcitabine in combination with
docetaxel and anti-VEGF therapy (bevacizumab))

L26 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2006:189335 USPATFULL
TITLE: Combination therapy
INVENTOR(S): Wedge, Stephen Robert, Cheshire, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006160775	A1	20060720
APPLICATION INFO.:	US 2004-563440	A1	20040707 (10)
	WO 2004-GB2937		20040707
			20060105 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-16123	20030710
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	817	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 219923-05-4, ZD6126 288383-20-0, AZD 2171 824933-09-7
(AZD2171-ZD6126 combination with optional ionizing radiation for production
of antiangiogenic and/or vascular permeability-reducing effect and
treatment of cancer)

=>
=> d his

(FILE 'HOME' ENTERED AT 14:19:21 ON 25 SEP 2007)

FILE 'REGISTRY' ENTERED AT 14:19:33 ON 25 SEP 2007
E AZD2171

E AZD2171/CN
E AZD 2171/CN
L1 1 S E3
E ZD 6126/CN
L2 1 S E3

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, USPATFULL, USPATOLD, USPAT2'
ENTERED AT 14:28:21 ON 25 SEP 2007

SET MSTEP ON

L3 0 FILE MEDLINE
L4 0 FILE BIOSIS
L5 0 FILE EMBASE
L6 40 FILE CAPLUS
L7 13 FILE USPATFULL
L8 0 FILE USPATOLD
L9 0 FILE USPAT2

TOTAL FOR ALL FILES

L10 53 S L1
L11 0 FILE MEDLINE
L12 73 FILE BIOSIS
L13 173 FILE EMBASE
L14 73 FILE CAPLUS
L15 12 FILE USPATFULL
L16 0 FILE USPATOLD
L17 1 FILE USPAT2

TOTAL FOR ALL FILES

L18 332 S L2
L19 0 FILE MEDLINE
L20 0 FILE BIOSIS
L21 0 FILE EMBASE
L22 3 FILE CAPLUS
L23 2 FILE USPATFULL
L24 0 FILE USPATOLD
L25 0 FILE USPAT2

TOTAL FOR ALL FILES

L26 5 S L18 AND L10

=> fil stnguide

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
49.77	85.38

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 15:40:34 ON 25 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 24, 2007 (20070924/UP).

=> d l1;d l2

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN


RN 288383-20-0 REGISTRY

ED Entered STN: 08 Sep 2000

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxyl]- (CA INDEX NAME)

OTHER NAMES:

CN 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
 CN AZD 2171
 CN Cediranib
 DR 790713-41-6
 MF C25 H27 F N4 O3
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, CA, CAPLUS, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

39 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 40 REFERENCES IN FILE CAPLUS (1907 TO DATE)

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 219923-05-4 REGISTRY
 ED Entered STN: 23 Feb 1999
 CN Acetamide, N-[(5S)-6,7-dihydro-9,10,11-trimethoxy-3-(phosphonooxy)-5H-dibenzo[a,c]cyclohepten-5-yl]- (CA INDEX NAME)
 OTHER NAMES:
 CN ANG 453
 CN AZD 6126
 CN N-Acetylcolchicinol dihydrogenphosphate
 CN ZD 6126
 CN ZM 445526
 FS STEREOSEARCH
 MF C20 H24 N O8 P
 CI COM
 SR CA
 LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, EMBASE, IMSRESEARCH, IPA, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

73 REFERENCES IN FILE CA (1907 TO DATE)
73 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil stnguide
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.66	92.16

FILE 'STNGUIDE' ENTERED AT 16:00:36 ON 25 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 24, 2007 (20070924/UP).

=>
=>
=>

=> fil stnguide
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
5.28	97.44

FILE 'STNGUIDE' ENTERED AT 16:53:13 ON 25 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 24, 2007 (20070924/UP).

=> d his

(FILE 'HOME' ENTERED AT 14:19:21 ON 25 SEP 2007)

FILE 'REGISTRY' ENTERED AT 14:19:33 ON 25 SEP 2007

	E AZD2171
	E AZD2171/CN
	E AZD 2171/CN
L1	1 S E3
	E ZD 6126/CN
L2	1 S E3

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, USPATFULL, USPATOLD, USPAT2'
ENTERED AT 14:28:21 ON 25 SEP 2007

	SET MSTEP ON
L3	0 FILE MEDLINE

L4 0 FILE BIOSIS
L5 0 FILE EMBASE
L6 40 FILE CAPLUS
L7 13 FILE USPATFULL
L8 0 FILE USPATOLD
L9 0 FILE USPAT2

TOTAL FOR ALL FILES

L10 53 S L1
L11 0 FILE MEDLINE
L12 73 FILE BIOSIS
L13 173 FILE EMBASE
L14 73 FILE CAPLUS
L15 12 FILE USPATFULL
L16 0 FILE USPATOLD
L17 1 FILE USPAT2

TOTAL FOR ALL FILES

L18 332 S L2
L19 0 FILE MEDLINE
L20 0 FILE BIOSIS
L21 0 FILE EMBASE
L22 3 FILE CAPLUS
L23 2 FILE USPATFULL
L24 0 FILE USPATOLD
L25 0 FILE USPAT2

TOTAL FOR ALL FILES

L26 5 S L18 AND L10

FILE 'STNGUIDE' ENTERED AT 15:40:34 ON 25 SEP 2007

FILE 'REGISTRY' ENTERED AT 15:52:14 ON 25 SEP 2007

FILE 'STNGUIDE' ENTERED AT 15:52:15 ON 25 SEP 2007

FILE 'REGISTRY' ENTERED AT 15:53:55 ON 25 SEP 2007

FILE 'STNGUIDE' ENTERED AT 15:53:56 ON 25 SEP 2007

FILE 'STNGUIDE' ENTERED AT 16:00:36 ON 25 SEP 2007

FILE 'STNGUIDE' ENTERED AT 16:53:13 ON 25 SEP 2007

=> fil MEDLINE, BIOSIS, EMBASE, CAPLUS, uspatall
COST IN U.S. DOLLARS.

SINCE FILE	TOTAL
ENTRY	SESSION
0.96	98.40

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 17:02:51 ON 25 SEP 2007

FILE 'BIOSIS' ENTERED AT 17:02:51 ON 25 SEP 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 17:02:51 ON 25 SEP 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 17:02:51 ON 25 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:02:51 ON 25 SEP 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:02:51 ON 25 SEP 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:02:51 ON 25 SEP 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l10 and py<=2003

L27 0 FILE MEDLINE
L28 0 FILE BIOSIS
L29 0 FILE EMBASE
L30 2 FILE CAPLUS
L31 2 FILE USPATFULL
L32 0 FILE USPATOLD
L33 0 FILE USPAT2

TOTAL FOR ALL FILES

L34 4 L10 AND PY<=2003

=> d l34 1-4 ibib kwic

L34 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:747609 CAPLUS

DOCUMENT NUMBER: 135:283196

TITLE: Therapeutic combinations of antihypertensive and
antiangiogenic agents

INVENTOR(S): Curwen, Jon Owen; Ogilvie, Donald James

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074360	A1	20011011	WO 2001-GB1522	20010402 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2401854	A1	20011011	CA 2001-2401854	20010402 <--
EP 1272186	A1	20030108	EP 2001-917305	20010402 <--
EP 1272186	B1	20070228		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001009729	A	20030204	BR 2001-9729	20010402 <--
HU 200300426	A2	20030628	HU 2003-426	20010402 <--
JP 2003528917	T	20030930	JP 2001-572104	20010402 <--
EE 200200578	A	20040615	EE 2002-578	20010402
NZ 520938	A	20050826	NZ 2001-520938	20010402
AT 355065	T	20060315	AT 2001-917305	20010402
EP 1658849	A2	20060524	EP 2006-3576	20010402

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

NZ 534455	A	20070126	NZ 2001-534455	20010402
EP 1790340	A2	20070530	EP 2007-3863	20010402
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
IN 2002MN01149	A	20050304	IN 2002-MN1149	20020823
ZA 2002006959	A	20031201	ZA 2002-6959	20020829 <--
US 2003144298	A1	20030731	US 2002-240413	20021001 <--
MX 2002PA09743	A	20030327	MX 2002-PA9743	20021003 <--
NO 2002004814	A	20021112	NO 2002-4814	20021004 <--
NO 323467	B1	20070521		
NO 2006002050	A	20011008	NO 2006-2050	20060508 <--
PRIORITY APPLN. INFO.:				
			GB 2000-8269	A 20000405
			EP 2001-917305	A3 20010402
			NZ 2001-520938	A1 20010402
			WO 2001-GB1522	W 20010402

OTHER SOURCE(S): MARPAT 135:283196

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI	WO 2001074360 A1	<u>20011011</u>			
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001074360	A1	20011011	WO 2001-GB1522	20010402 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2401854	A1	20011011	CA 2001-2401854	20010402 <--
	EP 1272186	A1	20030108	EP 2001-917305	20010402 <--
	EP 1272186	B1	20070228		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009729	A	20030204	BR 2001-9729	20010402 <--
	HU 200300426	A2	20030628	HU 2003-426	20010402 <--
	JP 2003528917	T	20030930	JP 2001-572104	20010402 <--
	EE 200200578	A	20040615	EE 2002-578	20010402
	NZ 520938	A	20050826	NZ 2001-520938	20010402
	AT 355065	T	20060315	AT 2001-917305	20010402
	EP 1658849	A2	20060524	EP 2006-3576	20010402
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 534455	A	20070126	NZ 2001-534455	20010402
	EP 1790340	A2	20070530	EP 2007-3863	20010402
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
	IN 2002MN01149	A	20050304	IN 2002-MN1149	20020823
	ZA 2002006959	A	20031201	ZA 2002-6959	20020829 <--
	US 2003144298	A1	20030731	US 2002-240413	20021001 <--
	MX 2002PA09743	A	20030327	MX 2002-PA9743	20021003 <--
	NO 2002004814	A	20021112	NO 2002-4814	20021004 <--
	NO 323467	B1	20070521		
	NO 2006002050	A	20011008	NO 2006-2050	20060508 <--
IT	62571-86-2, Captopril		76547-98-3, Lisinopril	288383-14-2	288383-15-3
	288383-16-4		288383-17-5	288383-18-6	288383-19-7, <u>288383-20-0</u>

288383-21-1 288383-22-2 288383-23-3 288383-24-4 288383-25-5

288383-26-6 443913-73-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic combinations of antihypertensive and antiangiogenic agents)

L34 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:573671 CAPLUS

DOCUMENT NUMBER: 133:177183

TITLE: Preparation of quinazoline derivatives as angiogenesis inhibitors

INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick; Stokes, Elaine Sophie Elizabeth; Mckerrecher, Darren

PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK; Zeneca-Pharma S.A.

SOURCE: PCT Int. Appl., 346 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047212	A1	20000817	WO 2000-GB373	20000208 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2362715	A1	20000817	CA 2000-2362715	20000208 <--
EP 1154774	A1	20011121	EP 2000-902730	20000208 <--
EP 1154774	B1	20050622		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102314	T2	20020121	TR 2001-2314	20000208 <--
BR 2000008128	A	20020213	BR 2000-8128	20000208 <--
HU 200104964	A2	20020429	HU 2001-4964	20000208 <--
JP 2002536414	T	20021029	JP 2000-598164	20000208 <--
JP 3893026	B2	20070314		
EE 200100409	A	20021216	EE 2001-409	20000208 <--
AU 763618	B2	20030731	AU 2000-24475	20000208 <--
NZ 513204	A	20040430	NZ 2000-513204	20000208
CN 1597667	A	20050323	CN 2004-10058982	20000208
TR 200500745	T2	20050523	TR 2005-745	20000208
NZ 530832	A	20050527	NZ 2000-530832	20000208
EP 1553097	A1	20050713	EP 2005-4285	20000208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 298237	T	20050715	AT 2000-902730	20000208
RU 2262935	C2	20051027	RU 2001-124816	20000208
PT 1154774	T	20051031	PT 2000-902730	20000208
ES 2242596	T3	20051116	ES 2000-902730	20000208
IN 2000DE00115	A	20050311	IN 2000-DE115	20000211
IN 2001MN00893	A	20070525	IN 2001-MN893	20010726
ZA 2001006340	A	20021101	ZA 2001-6340	20010801 <--

NO 2001003882	A	20011009	NO 2001-3882	20010809 <--
NO 321604	B1	20060612		
MX 2001PA08182	A	20030820	MX 2001-PA8182	20010810 <--
HK 1041212	A1	20051202	HK 2002-102781	20020412
US 7074800	B1	20060711	US 2002-913020	20020506
NO 2005002773	A	20011009	NO 2005-2773	20050608 <--
US 2006004017	A1	20060105	US 2005-169122	20050629
JP 2006273860	A	20061012	JP 2006-129249	20060508

PRIORITY APPLN. INFO..

EP 1999-400305	A	19990210
EP 2000-902730	A3	20000208
JP 2000-598164	A3	20000208
WO 2000-GB373	W	20000208
US 2002-913020	A3	20020506

OTHER SOURCE(S):

MARPAT 133:177183

REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2000047212 A1 20000817

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000047212	A1	20000817	WO 2000-GB373	20000208 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2362715	A1	20000817	CA 2000-2362715	20000208 <--
EP 1154774	A1	20011121	EP 2000-902730	20000208 <--
EP 1154774	B1	20050622		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102314	T2	20020121	TR 2001-2314	20000208 <--
BR 2000008128	A	20020213	BR 2000-8128	20000208 <--
HU 200104964	A2	20020429	HU 2001-4964	20000208 <--
JP 2002536414	T	20021029	JP 2000-598164	20000208 <--
JP 3893026	B2	20070314		
EE 200100409	A	20021216	EE 2001-409	20000208 <--
AU 763618	B2	20030731	AU 2000-24475	20000208 <--
NZ 513204	A	20040430	NZ 2000-513204	20000208
CN 1597667	A	20050323	CN 2004-10058982	20000208
TR 200500745	T2	20050523	TR 2005-745	20000208
NZ 530832	A	20050527	NZ 2000-530832	20000208
EP 1553097	A1	20050713	EP 2005-4285	20000208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 298237	T	20050715	AT 2000-902730	20000208
RU 2262935	C2	20051027	RU 2001-124816	20000208
PT 1154774	T	20051031	PT 2000-902730	20000208
ES 2242596	T3	20051116	ES 2000-902730	20000208
IN 2000DE00115	A	20050311	IN 2000-DE115	20000211
IN 2001MN00893	A	20070525	IN 2001-MN893	20010726
ZA 2001006340	A	20021101	ZA 2001-6340	20010801 <--
NO 2001003882	A	20011009	NO 2001-3882	20010809 <--
NO 321604	B1	20060612		
MX 2001PA08182	A	20030820	MX 2001-PA8182	20010810 <--
HK 1041212	A1	20051202	HK 2002-102781	20020412
US 7074800	B1	20060711	US 2002-913020	20020506
NO 2005002773	A	20011009	NO 2005-2773	20050608 <--

US 2006004017	A1	20060105	US 2005-169122	20050629
JP 2006273860	A	20061012	JP 2006-129249	20060508

IT 170147-76-9P, 5-Hydroxy-1-(tert-butoxycarbonyl)-2,3-dihydroindole
172078-33-0P, 5-Hydroxy-2,3-dihydro-1H-indole 288382-01-4P,
6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(2-naphthyloxy)quinazoline
288382-02-5P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(quinolin-7-
yloxy)quinazoline 288382-04-7P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-
methoxy-4-(quinolin-7-yloxy)quinazoline 288382-06-9P,
6-Methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-(quinolin-7-
yloxy)quinazoline 288382-10-5P, 4-(4-Chloroquinolin-7-yloxy)-6-methoxy-7-
(3-morpholinopropoxy)quinazoline 288382-12-7P, 6-Methoxy-7-[(1-
methylpiperidin-4-yl)methoxy]-4-(4-methylquinolin-7-yloxy)quinazoline
288382-14-9P, 6-Methoxy-4-(4-methylquinolin-7-yloxy)-7-[3-(pyrrolidin-1-
yl)propoxy]quinazoline 288382-16-1P, 6-Methoxy-7-[2-(2-
methoxyethoxy)ethoxy]-4-(quinolin-7-yloxy)quinazoline 288382-18-3P,
6-Methoxy-7-[[1-(2-(methylsulfonyl)ethyl)piperidin-4-yl]methoxy]-4-
(quinolin-7-yloxy)quinazoline 288382-20-7P, 4-(2,3-Dimethylindol-5-
yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
288382-22-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-
ylpropoxy)quinazoline 288382-24-1P, 6-Methoxy-7-(1-methylpiperidin-4-
ylmethoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288382-26-3P,
6-Methoxy-7-(3-pyrrolidin-1-ylpropoxy)-4-(2-trifluoromethylindol-5-
yloxy)quinazoline 288382-28-5P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-
[(1-methylpiperidin-3-yl)methoxy]quinazoline 288382-30-9P,
4-(Indol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline
288382-32-1P, 7-(3-(N,N-Dimethylamino)propoxy)-6-methoxy-4-(2-methylindol-
5-yloxy)quinazoline 288382-34-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-
[2-(2-morpholinoethoxy)ethoxy]quinazoline 288382-36-5P,
7-[2-(N,N-Diethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-
yloxy)quinazoline 288382-37-6P, 6-Methoxy-7-(3-piperidinopropoxy)-4-
(quinolin-7-yloxy)quinazoline 288382-38-7P, 4-(2-Methylindol-5-yloxy)-7-
(3-morpholinopropoxy)quinazoline 288382-39-8P, 4-(2-Methylindol-5-yloxy)-
7-[2-(piperidin-1-yl)ethoxy]quinazoline 288382-40-1P,
4-(2-Methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline
288382-41-2P, 6-Methoxy-7-(3-piperidinopropoxy)-4-(6-trifluoromethylindol-
5-yloxy)quinazoline 288382-42-3P, 7-[3-(Methylsulfonyl)propoxy]-4-(2-
methylindol-5-yloxy)quinazoline 288382-43-4P, 7-[3-(N,N-
Dimethylamino)propoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline
288382-44-5P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[(1-
methylpiperidin-3-yl)methoxy]quinazoline 288382-45-6P,
7-[2-(N,N-Diethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline
288382-46-7P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-
yl)ethoxy]quinazoline 288382-47-8P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-
(piperidin-1-yl)ethoxy]quinazoline 288382-48-9P, 4-(Indol-6-yloxy)-6-
methoxy-7-(3-morpholinopropoxy)quinazoline 288382-49-0P,
7-[3-(Ethylsulfonyl)propoxy]-6-methoxy-4-(2-methylindol-5-
yloxy)quinazoline 288382-50-3P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(3-
piperidinopropoxy)quinazoline 288382-51-4P, 7-(2-Hydroxy-3-
piperidinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline
288382-52-5P, 7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-
(2-methylindol-5-yloxy)quinazoline 288382-53-6P, 6-Methoxy-4-(2-
methylindol-5-yloxy)-7-[2-(N-methylamino)ethoxy]quinazoline
288382-54-7P, 7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(2-
methylindol-5-yloxy)quinazoline 288382-55-8P, 6-Methoxy-7-(3-
morpholinopropoxy)-4-(quinolin-7-yloxy)quinazoline 288382-56-9P,
6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-methylpiperidin-4-
yl)methoxy]quinazoline 288382-57-0P, 4-(Indol-5-yloxy)-6-methoxy-7-[(1-
methylpiperidin-4-yl)methoxy]quinazoline 288382-58-1P,
4-(Indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
288382-59-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-

methylsulfonylpropoxy)quinazoline 288382-60-5P, 7-[(1-(Cyanomethyl)piperidin-4-yl)methoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-61-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline 288382-62-7P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-pyrrolidin-1-ylethoxy)quinazoline 288382-63-8P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline 288382-64-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline 288382-65-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288382-66-1P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288382-67-2P, 6-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-68-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288382-69-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy]quinazoline 288382-70-7P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288382-71-8P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-72-9P 288382-73-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288382-74-1P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline 288382-75-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(piperidin-4-yloxy)ethoxy]quinazoline 288382-76-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(N-methyl-N-methylsulfonylamino)ethoxy]quinazoline 288382-77-4P, 7-[2-[[1-(2-Cyanoethyl)piperidin-4-yl]oxy]ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-78-5P, 4-(2-Methylindol-5-yloxy)-7-[3-(pyrrolidinyl)propoxy]quinazoline 288382-79-6P, 4-(2-Methylindol-5-yloxy)-7-[3-(1,1-dioxothiomorpholino)propoxy]quinazoline 288382-80-9P, 4-(2-Methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline 288382-81-0P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline 288382-82-1P, 7-[3-(N,N-Dimethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-83-2P, 7-[3-(N,N-Diethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-84-3P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-85-4P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288382-86-5P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-87-6P, 7-[[1-(2-Methoxyethyl)piperidin-4-yl]methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-88-7P, 7-(2-Hydroxy-3-morpholinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-89-8P, 7-[2-[1-(2-Methoxyethyl)piperidin-4-yl]ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-90-1P, 7-(2-Hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-91-2P, 7-[3-(N,N-Diethylamino)-2-hydroxypropoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-92-3P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-93-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288382-94-5P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288382-95-6P, (R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy)quinazoline 288382-96-7P, (R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-oxopyrrolidin-5-ylmethoxy)quinazoline 288382-97-8P, 4-(4-Bromoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-98-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-(2-(pyrrolidin-1-yl)ethyl)piperidin-4-yl]methoxy]quinazoline 288382-99-0P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-00-6P, (R)-7-(2-Hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-01-7P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-02-8P, (S)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-4-(indol-5-yloxy)-6-

methoxyquinazoline 288383-03-9P, (S)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-04-0P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-05-1P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-06-2P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-07-3P, (R)-7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-08-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-(2-morpholinoethyl)piperidin-4-yl]methoxy]quinazoline 288383-09-5P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-10-8P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-11-9P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)quinazoline 288383-12-0P, (S)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy)quinazoline 288383-13-1P, 4-(6-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-14-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-15-3P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-16-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-17-5P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-18-6P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-19-7P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-20-0P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-21-1P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-22-2P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-23-3P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-24-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-25-5P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline 288383-26-6P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-27-7P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-6-yloxy)quinazoline 288383-28-8P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(1-naphthyl)quinazoline 288383-29-9P, 6-Methoxy-4-(4-methylquinolin-7-yloxy)-7-(3-morpholinopropoxy)quinazoline 288383-33-5P, 6,7-Dimethoxy-4-(quinolin-7-yloxy)quinazoline 288383-34-6P, (S)-6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288383-35-7P, (R)-6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288383-37-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-(2-methylsulfonyl)ethyl]piperidin-4-yl]methoxy]quinazoline 288383-38-0P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yloxy)quinazoline 288383-39-1P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yloxy)quinazoline 288383-40-4P, 4-(2,4-Dimethylquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-41-5P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-((3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)quinazoline 288383-42-6P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-((3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)quinazoline 288383-43-7P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(quinolin-6-yloxy)quinazoline 288383-44-8P, 4-((1,3-Benzodioxol-5-yl)amino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-45-9P, 4-(1H-Indazol-6-ylamino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-46-0P, 4-(1H-Indazol-5-ylamino)-6-methoxy-7-(3-

morpholinopropoxy)quinazoline 288383-47-1P, 4-((1,3-Benzothiazol-6-yl)amino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-48-2P, 6-Methoxy-4-((2-methyl-1,3-benzothiazol-5-yl)amino)-7-(3-morpholinopropoxy)quinazoline 288383-49-3P, 4-(2,3-Dihydro-1H-inden-5-ylamino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-50-6P, 6-Methoxy-4-(2-methyl-4-oxo-4H-chromen-7-yloxy)-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-52-8P, 6-Methoxy-4-((4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-53-9P, 6-Methoxy-4-(2-methyl-4-oxo-4H-chromen-7-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-54-0P, 6-Methoxy-4-((4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-55-1P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride 288383-56-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline hydrochloride 288383-57-3P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline hydrochloride 288383-58-4P, 4-(2,4-Dimethylquinolin-7-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-59-5P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride 288383-60-8P, 6-Methoxy-4-(2-methylquinolin-7-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-61-9P, 6-Methoxy-7-[(1-(2-methylsulfonyl)ethyl)piperidin-4-yl)methoxy]-4-(2-methylquinolin-7-yloxy)quinazoline 288383-63-1P, 6-Methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-methylquinolin-7-yloxy)quinazoline 288383-66-4P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288383-67-5P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(2-methylquinolin-7-yloxy)quinazoline 288383-68-6P, 7-[2-(N,N-Dimethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-70-0P, 6-Methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-75-5P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-((1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)quinazoline 288383-76-6P, 6-Methoxy-7-[[1-(2-methoxyethyl)piperidin-4-yl]methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-81-3P, 7-(3-Chloropropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-82-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy]ethoxy]quinazoline 288383-84-6P, 6-Methoxy-4-(indol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-88-0P, 4-(2-Methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline 288383-89-1P, 4-(2-Methylindol-5-yloxy)-7-[3-(piperidin-1-yl)propoxy]quinazoline 288383-90-4P, 7-((1-(tert-Butoxycarbonyl)piperidin-4-yl)methoxy)-4-(2-methylindol-5-yloxy)quinazoline 288383-92-6P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 288383-94-8P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288383-95-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline 288383-96-0P, 7-[2-(N,N-Diethylamino)ethoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288383-97-1P, 7-[2-(N,N-Dimethylamino)ethoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline 288383-98-2P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline 288383-99-3P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(2-oxopyrrolidin-1-yl)ethoxy]quinazoline 288384-00-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-yl)ethoxy]quinazoline 288384-01-0P, 4-(2,3-Dimethylindol-5-yloxy)-7-[2-(2,5-dioxopyrrolidin-1-yl)ethoxy]-6-methoxyquinazoline 288384-02-1P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288384-03-2P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-04-3P, 4-(2,3-Dimethylindol-5-yloxy)-7-[3-(1,1-dioxothiomorpholino)propoxy]-6-methoxyquinazoline 288384-05-4P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(4-

pyridyloxy)ethoxy]quinazoline 288384-06-5P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-08-7P, 7-Benzyloxy-4-(indol-5-yloxy)-6-methoxyquinazoline 288384-09-8P, 7-[2-(N,N-Dimethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288384-10-1P, (S)-4-(Indol-5-yloxy)-6-methoxy-7-(1-methylpyrrolidin-2-yl)quinazoline 288384-11-2P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-12-3P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-14-5P, 4-(2,3-Dimethylindol-5-yloxy)-7-(3-ethylsulfonylpropoxy)-6-methoxyquinazoline 288384-16-7P, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-(3-morpholinopropoxy)quinazoline 288384-19-0P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[(E)-4-(pyrrolidin-1-yl)but-2-en-1-yloxy]quinazoline 288384-21-4P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(5-methyl-1H-[1,2,4]triazol-1-yl)propoxy]quinazoline 288384-24-7P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-25-8P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(1-methylimidazol-2-yl)ethoxy]quinazoline 288384-26-9P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288384-27-0P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(1,1-dioxothiomorpholino)propoxy]quinazoline 288384-28-1P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288384-29-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(2-furylmethoxy)quinazoline 288384-30-5P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(N,N-dimethylamino)ethoxy]quinazoline 288384-31-6P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 288384-32-7P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]quinazoline 288384-33-8P, 7-[2-(5,5-Dimethyl-1,3-dioxan-2-yl)ethoxy]-4-(2,3-dimethylindol-5-ylamino)-6-methoxyquinazoline 288384-34-9P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline 288384-35-0P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(pyridazin-4-yl)amino]ethoxy]quinazoline 288384-36-1P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(2-morpholinoethoxy)ethoxy]quinazoline 288384-37-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(3-pyridyl)ethoxy]quinazoline 288384-38-3P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(2-oxopyrrolidin-1-yl)propoxy]quinazoline 288384-39-4P, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288384-40-7P, 4-(1,2-Dimethylindol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288384-42-9P, 4-(Indol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-49-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-50-9P, 6-Methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]-4-(quinolin-7-yloxy)quinazoline 288384-51-0P, 6-Methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]-4-(4-methylquinolin-7-yloxy)quinazoline 288384-52-1P, 6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(4-trifluoromethylquinolin-7-yloxy)quinazoline 288384-57-6P, 4-(3-Fluoro-2-methylquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline 288384-59-8P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-63-4P, 4-(6-Methoxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-64-5P, 4-(Indol-4-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-65-6P, 4-(9H-Carbazol-3-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-67-8P, 4-[[7-Chloro-2-(ethoxycarbonyl)indol-5-yl]oxy]-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-69-0P, 7-Benzyloxy-4-[(1-tert-butoxycarbonyl-2,3-dimethylindol-5-yl)oxy]-6-methoxyquinazoline 288384-70-3P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-2-

yloxy)quinazoline 288384-71-4P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-5-yloxy)quinazoline 288384-75-8P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288384-76-9P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline 288384-78-1P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-82-7P, 4-(2-Carboxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-84-9P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(quinolin-7-yloxy)quinazoline 288384-85-0P, 4-(4-Chloroquinolin-7-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-87-2P, 6-Methoxy-4-((2-methyl-1,3-benzothiazol-5-yl)oxy)-7-(3-methylsulfonylpropoxy)quinazoline 288384-89-4P, 4-(7-Hydroxy-2-naphthyloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-93-0P, 4-(2-Chloro-1H-benzimidazol-6-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288384-95-2P, 6-Methoxy-4-(2-methyl-1H-benzimidazol-6-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288385-00-2P, 4-(3-Cyanoquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288385-10-4P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(1,2,3,4-tetrahydroquinolin-6-yloxy)quinazoline 288385-18-2P, 4-(2,3-Dihydro-1H-indol-5-yl)oxy-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288385-27-3P, 6-Methoxy-7-(2-piperidinoethoxy)-4-(quinolin-7-yloxy)quinazoline 288385-30-8P, 7-Benzoyloxy-6-methoxy-4-(quinolin-7-yloxy)quinazoline 288385-33-1P, 7-Hydroxy-6-methoxy-4-(quinolin-7-yloxy)quinazoline 288385-35-3P, 6-Methoxy-7-(2-morpholinoethoxy)-4-(quinolin-7-yloxy)quinazoline 288385-38-6P, (S)-6-Methoxy-7-(5-oxopyrrolidin-2-ylmethoxy)-4-(quinolin-7-yloxy)quinazoline 288385-39-7P, 4-(9H-Carbazol-2-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288385-41-1P, 7-[2-[N-(3,6-Dichloropyridazin-4-yl)-N-methylamino]ethoxy]-4-(indol-5-ylamino)-6-methoxyquinazoline 288385-43-3P, 4-(Indol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288385-44-4P, 4-(Indol-5-ylamino)-6-methoxy-7-[(3-pyridyl)methoxy]quinazoline 288385-45-5P, 4-(Indol-5-ylamino)-6-methoxy-7-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]quinazoline 288385-47-7P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(3-morpholinopropoxy)quinazoline 288385-49-9P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(2-methylindol-5-ylamino)quinazoline 288385-50-2P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(2-piperidinoethoxy)quinazoline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (angiogenesis inhibitor; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

L34 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2006:177591 USPATFULL
 TITLE: Quinazoline derivatives as angiogenesis inhibitors
 INVENTOR(S): Stokes, Elaine S E, Macclesfield, UNITED KINGDOM
 Mckerrecher, Darren, Macclesfield, UNITED KINGDOM
 Hennequin, Laurent F A, Reims, FRANCE
 Ple, Patrick, Reims, FRANCE
 PATENT ASSIGNEE(S): AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7074800	B1	20060711
	WO 2000047212		20000817
APPLICATION INFO.:	US 2000-913020		20000208 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-400305	19990210
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Raymond, Richard L.	
LEGAL REPRESENTATIVE:	Morgan, Lewis & Bockius LLP	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	12388	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
PI	US 7074800	B1 20060711
	WO 2000047212	20000817
IT	170147-76-9P, 5-Hydroxy-1-(tert-butoxycarbonyl)-2,3-dihydroindole	<--
	172078-33-0P, 5-Hydroxy-2,3-dihydro-1H-indole	288382-01-4P,
	6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(2-naphthyloxy)quinazoline	288382-02-5P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline
	288382-04-7P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(quinolin-7-yloxy)quinazoline	288382-06-9P, 6-Methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-(quinolin-7-yloxy)quinazoline
	288382-10-5P, 4-(4-Chloroquinolin-7-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline	288382-12-7P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(4-methylquinolin-7-yloxy)quinazoline
	288382-14-9P, 6-Methoxy-4-(4-methylquinolin-7-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline	288382-16-1P, 6-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-(quinolin-7-yloxy)quinazoline
	288382-18-3P, 6-Methoxy-7-[[1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline	288382-20-7P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline
	288382-22-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline	288382-24-1P, 6-Methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline
	288382-26-3P, 6-Methoxy-7-(3-pyrrolidin-1-ylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline	288382-28-5P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline
	288382-30-9P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline	288382-32-1P, 7-(3-(N,N-Dimethylamino)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline
	288382-34-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(2-morpholinoethoxy)ethoxy]quinazoline	288382-36-5P, 7-[2-(N,N-Diethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline
	288382-37-6P, 6-Methoxy-7-(3-piperidinopropoxy)-4-(quinolin-7-yloxy)quinazoline	288382-38-7P, 4-(2-Methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline
	288382-39-8P, 4-(2-Methylindol-5-yloxy)-7-[2-(piperidin-1-yl)ethoxy]quinazoline	288382-40-1P, 4-(2-Methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline
	288382-41-2P, 6-Methoxy-7-(3-piperidinopropoxy)-4-(6-trifluoromethylindol-5-yloxy)quinazoline	288382-42-3P, 7-[3-(Methylsulfonyl)propoxy]-4-(2-methylindol-5-yloxy)quinazoline
	288382-43-4P, 7-[3-(N,N-Dimethylamino)propoxy]-4-(2,3-dimethylindol-5-yloxy)-6-methoxyquinazoline	288382-44-5P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-3-yl)methoxy)quinazoline
	288382-45-6P, 7-[2-(N,N-Diethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline	288382-46-7P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-yl)ethoxy]quinazoline
	288382-47-8P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(piperidin-1-yl)ethoxy]quinazoline	288382-48-9P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline
	288382-49-0P,	

7-[3-(Ethylsulfonyl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-50-3P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288382-51-4P, 7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-52-5P, 7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-53-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(N-methylamino)ethoxy]quinazoline 288382-54-7P, 7-[2-Hydroxy-3-(isopropylamino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-55-8P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-7-yloxy)quinazoline 288382-56-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288382-57-0P, 4-(Indol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288382-58-1P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288382-59-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-methylsulfonylpropoxy)quinazoline 288382-60-5P, 7-[(1-(Cyanomethyl)piperidin-4-yl)methoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-61-6P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline 288382-62-7P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-pyrrolidin-1-ylethoxy)quinazoline 288382-63-8P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline 288382-64-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline 288382-65-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288382-66-1P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline 288382-67-2P, 6-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-68-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]quinazoline 288382-69-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy]quinazoline 288382-70-7P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline 288382-71-8P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-72-9P, 288382-73-0P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288382-74-1P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline 288382-75-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(piperidin-4-yloxy)ethoxy]quinazoline 288382-76-3P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(N-methyl-N-methylsulfonylamino)ethoxy]quinazoline 288382-77-4P, 7-[2-[[1-(2-Cyanoethyl)piperidin-4-yl]oxy]ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-78-5P, 4-(2-Methylindol-5-yloxy)-7-[3-(pyrrolidinyl)propoxy]quinazoline 288382-79-6P, 4-(2-Methylindol-5-yloxy)-7-[3-(1,1-dioxothiomorpholino)propoxy]quinazoline 288382-80-9P, 4-(2-Methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline 288382-81-0P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline 288382-82-1P, 7-[3-(N,N-Dimethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-83-2P, 7-[3-(N,N-Diethylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-84-3P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288382-85-4P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288382-86-5P, 4-(Indol-6-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-87-6P, 7-[[1-(2-Methoxyethyl)piperidin-4-yl]methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288382-88-7P, 7-(2-Hydroxy-3-morpholinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-89-8P, 7-[2-[1-(2-Methoxyethyl)piperidin-4-yl]ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-90-1P, 7-(2-Hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-91-2P, 7-[3-(N,N-Diethylamino)-2-hydroxypropoxy]-6-methoxy-4-(2-methylindol-5-

yloxy)quinazoline 288382-92-3P, 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288382-93-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-(4-pyridyloxy)ethoxy]quinazoline 288382-94-5P, 4-(Indol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288382-95-6P, (R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy)quinazoline 288382-96-7P, (R)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-oxopyrrolidin-5-ylmethoxy)quinazoline 288382-97-8P, 4-(4-Bromoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288382-98-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-[2-(pyrrolidin-1-yl)ethyl]piperidin-4-yl]methoxy]quinazoline 288382-99-0P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-00-6P, (R)-7-(2-Hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-01-7P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-02-8P, (S)-7-[2-Hydroxy-3-(N,N-diisopropylamino)propoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-03-9P, (S)-7-(2-Hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline 288383-04-0P, (R)-7-(2-Hydroxy-3-piperidinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-05-1P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(3-methylindol-5-yloxy)quinazoline 288383-06-2P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-07-3P, (R)-7-[2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-08-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-(2-morpholinoethyl)piperidin-4-yl]methoxy]quinazoline 288383-09-5P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-10-8P, 4-(3-Fluoroquinolin-7-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-11-9P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)quinazoline 288383-12-0P, (S)-6-Methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy)quinazoline 288383-13-1P, 4-(6-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-14-2P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-15-3P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazoline 288383-16-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-17-5P, 4-(6-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-18-6P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-19-7P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-20-0P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-21-1P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288383-22-2P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-23-3P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazoline 288383-24-4P, 4-(4-Fluoroindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-25-5P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline 288383-26-6P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinazoline 288383-27-7P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-6-yloxy)quinazoline 288383-28-8P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(1-naphthyloxy)quinazoline 288383-29-9P, 6-Methoxy-4-(4-methylquinolin-7-yloxy)-7-(3-morpholinopropoxy)quinazoline 288383-33-5P, 6,7-Dimethoxy-4-(quinolin-7-yloxy)quinazoline 288383-34-6P, (S)-6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(quinolin-7-

yl oxy)quinazoline 288383-35-7P, (R)-6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(quinolin-7-yloxy)quinazoline 288383-37-9P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[[1-(2-methylsulfonyl ethyl)piperidin-4-yl]methoxy]quinazoline 288383-38-0P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yloxy)quinazoline 288383-39-1P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(2,2,4-trimethyl-1,2-dihydroquinolin-6-yloxy)quinazoline 288383-40-4P, 4-(2,4-Dimethylquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-41-5P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy]quinazoline 288383-42-6P, 6-Methoxy-7-[3-(pyrrolidin-1-yl)propoxy]-4-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy]quinazoline 288383-43-7P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(quinolin-6-yloxy)quinazoline 288383-44-8P, 4-[(1,3-Benzodioxol-5-yl)amino]-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-45-9P, 4-(1H-Indazol-6-ylamino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-46-0P, 4-(1H-Indazol-5-ylamino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-47-1P, 4-[(1,3-Benzothiazol-6-yl)amino]-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-48-2P, 6-Methoxy-4-[(2-methyl-1,3-benzothiazol-5-yl)amino]-7-(3-morpholinopropoxy)quinazoline 288383-49-3P, 4-(2,3-Dihydro-1H-inden-5-ylamino)-6-methoxy-7-(3-morpholinopropoxy)quinazoline 288383-50-6P, 6-Methoxy-4-(2-methyl-4-oxo-4H-chromen-7-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-52-8P, 6-Methoxy-4-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy]-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288383-53-9P, 6-Methoxy-4-(2-methyl-4-oxo-4H-chromen-7-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-54-0P, 6-Methoxy-4-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl)oxy]-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-55-1P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride 288383-56-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline hydrochloride 288383-57-3P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline hydrochloride 288383-58-4P, 4-(2,4-Dimethylquinolin-7-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-59-5P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride 288383-60-8P, 6-Methoxy-4-(2-methylquinolin-7-yloxy)-7-(3-pyrrolidin-1-ylpropoxy)quinazoline 288383-61-9P, 6-Methoxy-7-[(1-(2-methylsulfonyl ethyl)piperidin-4-yl)methoxy]-4-(2-methylquinolin-7-yloxy)quinazoline 288383-63-1P, 6-Methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-methylquinolin-7-yloxy)quinazoline 288383-66-4P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline 288383-67-5P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(2-methylquinolin-7-yloxy)quinazoline 288383-68-6P, 7-[2-(N,N-Dimethylamino)ethoxy]-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-70-0P, 6-Methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-75-5P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[(1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy]quinazoline 288383-76-6P, 6-Methoxy-7-[[1-(2-methoxyethyl)piperidin-4-yl]methoxy]-4-(2-methylindol-5-yloxy)quinazoline 288383-81-3P, 7-(3-Chloropropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline 288383-82-4P, 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[2-[[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy]ethoxy]quinazoline 288383-84-6P, 6-Methoxy-4-(indol-6-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-88-0P, 4-(2-Methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline 288383-89-1P, 4-(2-Methylindol-5-yloxy)-7-[3-(piperidin-1-yl)propoxy]quinazoline 288383-90-4P, 7-[(1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy]-4-(2-methylindol-5-

yloxy)quinazoline 288383-92-6P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-
 7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 288383-94-8P,
 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(1H-1,2,4-triazol-1-
 yl)ethoxy]quinazoline 288383-95-9P, 4-(2,3-Dimethylindol-5-yloxy)-6-
 methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinazoline 288383-96-0P,
 7-[2-(N,N-Diethylamino)ethoxy]-4-(2,3-dimethylindol-5-yloxy)-6-
 methoxyquinazoline 288383-97-1P, 7-[2-(N,N-Dimethylamino)ethoxy]-4-(2,3-
 dimethylindol-5-yloxy)-6-methoxyquinazoline 288383-98-2P,
 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(2-morpholinoethoxy)quinazoline
 288383-99-3P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(2-
 oxopyrrolidin-1-yl)ethoxy]quinazoline 288384-00-9P,
 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(piperidin-2-
 yl)ethoxy]quinazoline 288384-01-0P, 4-(2,3-Dimethylindol-5-yloxy)-7-[2-
 (2,5-dioxopyrrolidin-1-yl)ethoxy]-6-methoxyquinazoline 288384-02-1P,
 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-(3-
 morpholinopropoxy)quinazoline 288384-03-2P, 4-(2,3-Dimethylindol-5-
 yloxy)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-methylamino]ethoxy]quinazolin
 e 288384-04-3P, 4-(2,3-Dimethylindol-5-yloxy)-7-[3-(1,1-
 dioxothiomorpholino)propoxy]-6-methoxyquinazoline 288384-05-4P,
 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[2-(4-
 pyridyloxy)ethoxy]quinazoline 288384-06-5P, 4-(2,3-Dimethylindol-5-
 yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-08-7P,
 7-Benzoyloxy-4-(indol-5-yloxy)-6-methoxyquinazoline 288384-09-8P,
 7-[2-(N,N-Dimethylamino)ethoxy]-4-(indol-5-yloxy)-6-methoxyquinazoline
 288384-10-1P, (S)-4-(Indol-5-yloxy)-6-methoxy-7-(1-methylpyrrolidin-2-
 yl)quinazoline 288384-11-2P, 4-(Indol-5-yloxy)-6-methoxy-7-[2-[N-(2-
 methoxyethyl)-N-methylamino]ethoxy]quinazoline 288384-12-3P,
 4-(Indol-6-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline
 288384-14-5P, 4-(2,3-Dimethylindol-5-yloxy)-7-(3-ethylsulfonylpropoxy)-6-
 methoxyquinazoline 288384-16-7P, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-
 (3-morpholinopropoxy)quinazoline 288384-19-0P, 4-(2,3-Dimethylindol-5-
 ylamino)-6-methoxy-7-[(E)-4-(pyrrolidin-1-yl)but-2-en-1-yloxy]quinazoline
 288384-21-4P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(5-methyl-1H-
 [1,2,4]triazol-1-yl)propoxy]quinazoline 288384-24-7P,
 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-(2-methoxyethyl)-N-
 methylamino]ethoxy]quinazoline 288384-25-8P, 4-(2,3-Dimethylindol-5-
 ylamino)-6-methoxy-7-[2-(1-methylimidazol-2-yl)ethoxy]quinazoline
 288384-26-9P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(4-
 methylpiperazin-1-yl)propoxy]quinazoline 288384-27-0P,
 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[3-(1,1-
 dioxothiomorpholino)propoxy]quinazoline 288384-28-1P,
 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(4-
 pyridyl)amino]ethoxy]quinazoline 288384-29-2P, 4-(2,3-Dimethylindol-5-
 ylamino)-6-methoxy-7-(2-furylmethoxy)quinazoline 288384-30-5P,
 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(N,N-
 dimethylamino)ethoxy]quinazoline 288384-31-6P, 4-(2,3-Dimethylindol-5-
 ylamino)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline
 288384-32-7P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[2-(2-
 methoxyethoxy)ethoxy]ethoxy]quinazoline 288384-33-8P,
 7-[2-(5,5-Dimethyl-1,3-dioxan-2-yl)ethoxy]-4-(2,3-dimethylindol-5-
 ylamino)-6-methoxyquinazoline 288384-34-9P, 4-(2,3-Dimethylindol-5-
 ylamino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline 288384-35-0P,
 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(pyridazin-4-
 yl)amino]ethoxy]quinazoline 288384-36-1P, 4-(2,3-Dimethylindol-5-
 ylamino)-6-methoxy-7-[2-(2-morpholinoethoxy)ethoxy]quinazoline
 288384-37-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(3-
 pyridyl)ethoxy]quinazoline 288384-38-3P, 4-(2,3-Dimethylindol-5-
 ylamino)-6-methoxy-7-[3-(2-oxopyrrolidin-1-yl)propoxy]quinazoline
 288384-39-4P, 6-Methoxy-4-(2-methylindol-6-yloxy)-7-[3-(pyrrolidin-1-
 yl)propoxy]quinazoline 288384-40-7P, 4-(1,2-Dimethylindol-5-yloxy)-6-

methoxy-7-(3-morpholinopropoxy)quinazoline 288384-42-9P,
 4-(Indol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-49-6P,
 6-Methoxy-4-(2-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-50-9P,
 6-Methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]-4-(quinolin-7-yloxy)quinazoline 288384-51-0P, 6-Methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]-4-(4-methylquinolin-7-yloxy)quinazoline 288384-52-1P, 6-Methoxy-7-[(1-methylpiperidin-3-yl)methoxy]-4-(4-trifluoromethylquinolin-7-yloxy)quinazoline 288384-57-6P,
 4-(3-Fluoro-2-methylquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-3-yl)methoxy]quinazoline 288384-59-8P, 4-(2,3-Dimethylindol-5-yloxy)-6-methoxy-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-63-4P, 4-(6-Methoxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-64-5P, 4-(Indol-4-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-65-6P, 4-(9H-Carbazol-3-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-67-8P,
 4-[[7-Chloro-2-(ethoxycarbonyl)indol-5-yl]oxy]-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-69-0P, 7-Benzyloxy-4-[(1-tert-butoxycarbonyl-2,3-dimethylindol-5-yl)oxy]-6-methoxyquinazoline 288384-70-3P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-2-yloxy)quinazoline 288384-71-4P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(quinolin-5-yloxy)quinazoline 288384-75-8P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288384-76-9P,
 6-Methoxy-4-(3-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline 288384-78-1P, 6-Methoxy-4-(3-methylindol-5-yloxy)-7-[3-(N-methyl-N-methylsulfonylamino)propoxy]quinazoline 288384-82-7P,
 4-(2-Carboxyindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline 288384-84-9P, 6-Methoxy-7-(3-methylsulfonylpropoxy)-4-(quinolin-7-yloxy)quinazoline 288384-85-0P, 4-(4-Chloroquinolin-7-yloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-87-2P,
 6-Methoxy-4-[(2-methyl-1,3-benzothiazol-5-yl)oxy]-7-(3-methylsulfonylpropoxy)quinazoline 288384-89-4P, 4-(7-Hydroxy-2-naphthyloxy)-6-methoxy-7-(3-methylsulfonylpropoxy)quinazoline 288384-93-0P, 4-(2-Chloro-1H-benzimidazol-6-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288384-95-2P,
 6-Methoxy-4-(2-methyl-1H-benzimidazol-6-yloxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288385-00-2P, 4-(3-Cyanoquinolin-7-yloxy)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 288385-10-4P, 6-Methoxy-7-(3-morpholinopropoxy)-4-(1,2,3,4-tetrahydroquinolin-6-yloxy)quinazoline 288385-18-2P, 4-(2,3-Dihydro-1H-indol-5-yl)oxy-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288385-27-3P,
 6-Methoxy-7-(2-piperidinoethoxy)-4-(quinolin-7-yloxy)quinazoline 288385-30-8P, 7-Benzyloxy-6-methoxy-4-(quinolin-7-yloxy)quinazoline 288385-33-1P, 7-Hydroxy-6-methoxy-4-(quinolin-7-yloxy)quinazoline 288385-35-3P, 6-Methoxy-7-(2-morpholinoethoxy)-4-(quinolin-7-yloxy)quinazoline 288385-38-6P, (S)-6-Methoxy-7-(5-oxopyrrolidin-2-yl)methoxy-4-(quinolin-7-yloxy)quinazoline 288385-39-7P,
 4-(9H-Carbazol-2-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288385-41-1P, 7-[2-[N-(3,6-Dichloropyridazin-4-yl)-N-methylamino]ethoxy]-4-(indol-5-ylamino)-6-methoxyquinazoline 288385-43-3P, 4-(Indol-5-ylamino)-6-methoxy-7-[2-[N-methyl-N-(4-pyridyl)amino]ethoxy]quinazoline 288385-44-4P, 4-(Indol-5-ylamino)-6-methoxy-7-[(3-pyridyl)methoxy]quinazoline 288385-45-5P,
 4-(Indol-5-ylamino)-6-methoxy-7-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]quinazoline 288385-47-7P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(3-morpholinopropoxy)quinazoline 288385-49-9P,
 7-[3-(1,1-Dioxothiomorpholino)propoxy]-6-methoxy-4-(2-methylindol-5-ylamino)quinazoline

(angiogenesis inhibitor; preparation of quinazolines as angiogenesis

inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

L34 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2003:207937 USPATFULL

TITLE: Therapeutic combinations of antihypertensive and antiangiogenics agents

INVENTOR(S): Curwen, Jon Owen, Macclesfield, UNITED KINGDOM
Ogilvie, Donald James, Macclesfield, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003144298	A1	20030731	<--
APPLICATION INFO.:	US 2002-240413	A1	20021001	(10)
	WO 2001-GB1522		20010402	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-8269	20000405
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	1324	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2003144298 A1 20030731 <--

IT 62571-86-2, Captopril 76547-98-3, Lisinopril 288383-14-2
288383-15-3 288383-16-4 288383-17-5 288383-18-6 288383-19-7
288383-20-0 288383-21-1 288383-22-2 288383-23-3
288383-24-4 288383-25-5 288383-26-6 443913-73-3

(therapeutic combinations of antihypertensive and antiangiogenic agents)

=> FIL STNGUIDE